Omeros Jumps Most Ever on Novo License Deal for Zaltenibart (1)

(Updates stock move, adds analyst commentary.)

Omeros shares soar as much as 195%, most intraday on record, after the biotech and Novo Nordisk entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart in clinical development to treat rare blood and kidney disorders.

• HCW (buy) analyst Brandon Folkes views the “transaction as a significant positive, and upside to our prior assumptions”
  • Raises PT to $20 from $9

ADDITIONAL DETAILS

• Under the terms of the agreement, Novo will get exclusive global rights to develop and commercialize zaltenibart in all indications
• Omeros is eligible to receive $340m in ...